Strong Q3, Improved Guidance Are Signs Takeda Pharmaceutical May Be Undervalued
Takeda Pharmaceutical's strong earnings, dividends, and strategic moves make it an appealing investment despite US policy ...
Takeda Pharmaceutical: Strong Financials, Strategic Leadership Change, and Robust Pipeline Justify Buy Rating
Koichi Mamegano, an analyst from Bank of America Securities, maintained the Buy rating on Takeda Pharmaceutical Co (TKPHF – Research Report).
Takeda Prevails Over Sales Rep's Race, Disability Bias Claims
Takeda Pharmaceuticals America Inc. convinced a federal court to toss an employee’s claims that the company discriminated against her for being a White woman with depression and PTSD.
Celebrating the Legacy of Excellence and Innovation, Zydus Takeda Healthcare marks 25 years of manufacturing operations in India
Zydus Takeda Healthcare Private Limited (ZTHPL), a joint venture company set up by Zydus Lifesciences Limited and Takeda ...
Takeda Pharmaceutical Co.: Hold Rating Amid Mixed Q3 Results, Upward Guidance Revision, and Strategic Moves
Miki Sogi, an analyst from Bernstein, maintained the Hold rating on Takeda Pharmaceutical Co (TKPHF – Research Report). The associated price ...
Takeda Pharmaceutical Company Limited (TAK) Q3 2025 Earnings Call Transcript
Takeda Pharmaceutical Company Limited ( NYSE: TAK) Q3 2025 Results Conference Call January 30, 2025 5:30 AM ET Christopher O’Reilly - Head, Investor Relations Christophe Weber - President and Chief ...
ジャパンタイムズ2d
Takeda picks first female CEO of centuries-old drugmaker
Julie Kim, 54, has been running Takeda’s U.S. operations since 2022 and will assume the role of CEO in June next year, ...
Nikkei Asia2d
Japan's Takeda names 1st female CEO in leadership change
TOKYO -- Japan's Takeda Pharmaceutical announced on Thursday that CEO Christophe Weber will step down in June 2026 and be succeeded by current U.S. business head Julie Kim, who would become the ...